246 related articles for article (PubMed ID: 12709777)
1. Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans.
Grillon C; Cordova J; Levine LR; Morgan CA
Psychopharmacology (Berl); 2003 Aug; 168(4):446-54. PubMed ID: 12709777
[TBL] [Abstract][Full Text] [Related]
2. Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors.
Helton DR; Tizzano JP; Monn JA; Schoepp DD; Kallman MJ
J Pharmacol Exp Ther; 1998 Feb; 284(2):651-60. PubMed ID: 9454811
[TBL] [Abstract][Full Text] [Related]
3. The anxiolytic action of mGlu2/3 receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam.
Tizzano JP; Griffey KI; Schoepp DD
Pharmacol Biochem Behav; 2002 Sep; 73(2):367-74. PubMed ID: 12117591
[TBL] [Abstract][Full Text] [Related]
4. Group II metabotropic glutamate receptors within the amygdala regulate fear as assessed with potentiated startle in rats.
Walker DL; Rattiner LM; Davis M
Behav Neurosci; 2002 Dec; 116(6):1075-83. PubMed ID: 12492306
[TBL] [Abstract][Full Text] [Related]
5. Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition.
Schlumberger C; Schäfer D; Barberi C; Morè L; Nagel J; Pietraszek M; Schmidt WJ; Danysz W
Behav Pharmacol; 2009 Feb; 20(1):56-66. PubMed ID: 19179851
[TBL] [Abstract][Full Text] [Related]
6. Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice.
Linden AM; Shannon H; Baez M; Yu JL; Koester A; Schoepp DD
Psychopharmacology (Berl); 2005 Apr; 179(1):284-91. PubMed ID: 15619115
[TBL] [Abstract][Full Text] [Related]
7. Benzodiazepines have no effect on fear-potentiated startle in humans.
Baas JM; Grillon C; Böcker KB; Brack AA; Morgan CA; Kenemans JL; Verbaten MN
Psychopharmacology (Berl); 2002 May; 161(3):233-47. PubMed ID: 12021826
[TBL] [Abstract][Full Text] [Related]
8. Dipeptides as effective prodrugs of the unnatural amino acid (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a selective group II metabotropic glutamate receptor agonist.
Bueno AB; Collado I; de Dios A; Domínguez C; Martín JA; Martín LM; Martínez-Grau MA; Montero C; Pedregal C; Catlow J; Coffey DS; Clay MP; Dantzig AH; Lindstrom T; Monn JA; Jiang H; Schoepp DD; Stratford RE; Tabas LB; Tizzano JP; Wright RA; Herin MF
J Med Chem; 2005 Aug; 48(16):5305-20. PubMed ID: 16078848
[TBL] [Abstract][Full Text] [Related]
9. LY354740 affects startle responding but not sensorimotor gating or discriminative effects of phencyclidine.
Schreiber R; Lowe D; Voerste A; De Vry J
Eur J Pharmacol; 2000 Jan; 388(2):R3-4. PubMed ID: 10666513
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of alprazolam on the baseline and fear-potentiated startle reflex in humans: a dose-response study.
Riba J; Rodríguez-Fornells A; Urbano G; Morte A; Antonijoan R; Barbanoj MJ
Psychopharmacology (Berl); 2001 Oct; 157(4):358-67. PubMed ID: 11605094
[TBL] [Abstract][Full Text] [Related]
11. (2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-methylcyclopropyl) glycine is a potent and selective metabotropic group 2 receptor agonist with anxiolytic properties.
Collado I; Pedregal C; Mazón A; Espinosa JF; Blanco-Urgoiti J; Schoepp DD; Wright RA; Johnson BG; Kingston AE
J Med Chem; 2002 Aug; 45(17):3619-29. PubMed ID: 12166935
[TBL] [Abstract][Full Text] [Related]
12. Anxiolytic activity of the MGLU2/3 receptor agonist LY354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions.
Linden AM; Greene SJ; Bergeron M; Schoepp DD
Neuropsychopharmacology; 2004 Mar; 29(3):502-13. PubMed ID: 14694349
[TBL] [Abstract][Full Text] [Related]
13. Anxiolytic effects of buspirone and gepirone in the fear-potentiated startle paradigm.
Kehne JH; Cassella JV; Davis M
Psychopharmacology (Berl); 1988; 94(1):8-13. PubMed ID: 2894703
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effects of diazepam on the fear-potentiated startle reflex and the fear-inhibited light reflex in man.
Bitsios P; Philpott A; Langley RW; Bradshaw CM; Szabadi E
J Psychopharmacol; 1999; 13(3):226-34. PubMed ID: 10512076
[TBL] [Abstract][Full Text] [Related]
15. Interactions between LY354740, a group II metabotropic agonist and the GABA(A)-benzodiazepine receptor complex in the rat elevated plus-maze.
Ferris P; Seward E; Dawson GR
J Psychopharmacol; 2001 Jun; 15(2):76-82. PubMed ID: 11448091
[TBL] [Abstract][Full Text] [Related]
16. Validating a human model for anxiety using startle potentiated by cue and context: the effects of alprazolam, pregabalin, and diphenhydramine.
Baas JM; Mol N; Kenemans JL; Prinssen EP; Niklson I; Xia-Chen C; Broeyer F; van Gerven J
Psychopharmacology (Berl); 2009 Jul; 205(1):73-84. PubMed ID: 19415242
[TBL] [Abstract][Full Text] [Related]
17. Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344.
Rorick-Kehn LM; Perkins EJ; Knitowski KM; Hart JC; Johnson BG; Schoepp DD; McKinzie DL
J Pharmacol Exp Ther; 2006 Feb; 316(2):905-13. PubMed ID: 16223873
[TBL] [Abstract][Full Text] [Related]
18. Antagonists at the serotonin-3 receptor can reduce the fear-potentiated startle response in the rat: evidence for different types of anxiolytic activity?
Nevins ME; Anthony EW
J Pharmacol Exp Ther; 1994 Jan; 268(1):248-54. PubMed ID: 7905528
[TBL] [Abstract][Full Text] [Related]
19. The anxiolytic effect on the fear-potentiated startle is not due to a non-specific disruption.
Joordens RJ; Hijzen TH; Olivier B
Life Sci; 1998; 63(25):2227-32. PubMed ID: 9870708
[TBL] [Abstract][Full Text] [Related]
20. The GABA(B) receptor positive modulator BHF177 attenuated anxiety, but not conditioned fear, in rats.
Li X; Kaczanowska K; Finn MG; Markou A; Risbrough VB
Neuropharmacology; 2015 Oct; 97():357-64. PubMed ID: 26002628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
